Table 6. Adverse events during chemotherapy and chemoradiotherapy – events of grade ≥2 during chemotherapy or chemoradiotherapy.

Regime	Adverse Events: Number of events/ total number of patients	Adverse Event Description
Epirubicin, Oxaliplatin, Capecitabine (EOX)	0/15
Epirubicin, Cisplatin, Capecitabine (ECX)	18/71	Neutropenia– 3 Acute kidney injury – 9 Proximal lower limb deep vein thrombosis – 2 Pulmonary embolism – 1 Cerebrovascular accident - 2 Dysphagia and stent placement – 1 Death – 2
Epirubicin, Cisplatin, 5-Fluorouracil (ECF)	1/3	Neutropenia– 1
STO3 trial – ECX alone	1/4	Pulmonary embolism – 1
STO3 trial –ECX + Bevacizumab	1/4	Oesophageal perforation - 1
OEO5 trial – ECX alone	1/2	Death - 1
OEO5 trial – Cisplatin and 5-Fluorouracil	0/6
CROSS trial – Carboplatin, Paclitaxel with concurrent radiotherapy	0/10
NEOSCOPE trial – Oxaliplatin and Capecitabine with concurrent radiotherapy	1/6	Death - 1
NEOSCOPE trial –Carboplatin and Paclitaxel with concurrent radiotherapy	0/3
Herceptin, Cisplatin and Capecitabine	0/2
Capecitabine alone	0/1
Cisplatin alone	4/5	Death – 1 Neutropenia – 1 Acute kidney injury– 1 Acute psychosis - 1

Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. Neutropenia is defined as absolute neutrophil count <1.0 ×10 ⁹/L; Creatinine >1.5 upper limit for normal

Of 132 patients receiving NAC/CRT; 86% underwent chemotherapy alone (38 patients (34%) incomplete treatment) and 14% underwent chemoradiotherapy (1 patient (5%) incomplete treatment). Acute kidney injury with a rise in serum creatinine more than 1.5 times the upper limit of normal was the most common adverse event encountered. Five deaths were recorded during NAC/CRT.